Challenges in the development of high protein concentration formulations.

Development of formulations for protein drugs requiring high dosing (in the order of mg/kg) may become challenging for solubility limited proteins and for the subcutaneous (SC) route with <1.5 mL allowable administration volume that requires >100 mg/mL protein concentrations. Development of high protein concentration formulations also results in several manufacturing, stability, analytical, and delivery challenges. The high concentrations achieved by small scale approaches used in preformulation studies would have to be confirmed with manufacturing scale processes and with representative materials because of the lability of protein conformation and the propensity to interact with surfaces and solutes which render protein solubilities that are dependent on the process of concentrating. The concentration dependent degradation route of aggregation is the greatest challenge to developing protein formulations at these higher concentrations. In addition to the potential for nonnative protein aggregation and particulate formation, reversible self-association may occur, which contributes to properties such as viscosity that complicates delivery by injection. Higher viscosity also complicates manufacturing of high protein concentrations by filtration approaches. Chromatographic and electrophoretic assays may not accurately determine the non-covalent higher molecular weight forms because of the dilutions that are usually encountered with these techniques. Hence, techniques must be used that allow for direct measurement in the formulation without substantial dilution of the protein. These challenges are summarized in this review.

[1]  Joseph P. Remington,et al.  Remington's pharmaceutical sciences , 2016 .

[2]  S J Prestrelski,et al.  Precipitation of proteins in supercritical carbon dioxide. , 1996, Journal of pharmaceutical sciences.

[3]  L. J. Harris,et al.  Crystallization of intact monoclonal antibodies , 1995, Proteins.

[4]  C. Cantor,et al.  Biophysical Chemistry: Part II: Techniques for the Study of Biological Structure and Function , 1980 .

[5]  A. Minton Analytical centrifugation with preparative ultracentrifuges. , 1989, Analytical biochemistry.

[6]  Michael J. Pikal,et al.  Freeze‐Drying of Proteins. Process, Formulation, and Stability. , 1995 .

[7]  J. M. Schurr,et al.  Dynamic light scattering of biopolymers and biocolloids. , 1977, CRC critical reviews in biochemistry.

[8]  Michael J. Pikal,et al.  Rational Design of Stable Lyophilized Protein Formulations: Some Practical Advice , 1997, Pharmaceutical Research.

[9]  R. Langer,et al.  Formulation and delivery of proteins and peptides , 1994 .

[10]  M. Cromwell,et al.  Kinetics and thermodynamics of dimer formation and dissociation for a recombinant humanized monoclonal antibody to vascular endothelial growth factor. , 1999, Biochemistry.

[11]  T. Arakawa,et al.  Size-exclusion chromatography with on-line light-scattering, absorbance, and refractive index detectors for studying proteins and their interactions. , 1996, Analytical biochemistry.

[12]  T. Arakawa,et al.  Protein–Solvent Interactions in Pharmaceutical Formulations , 1991, Pharmaceutical Research.

[13]  V. Bloomfield,et al.  Quasi-elastic light scattering applications in biochemistry and biology. , 1981, Annual review of biophysics and bioengineering.

[14]  V. Lee Peptide and protein drug delivery , 1991 .

[15]  G. Winter,et al.  Formulation of proteins in vacuum-dried glasses. II. Process and storage stability in sugar-free amino acid systems. , 1999, Pharmaceutical development and technology.

[16]  P. York,et al.  Supercritical fluid processing of proteins: lysozyme precipitation from aqueous solution , 2003, The Journal of pharmacy and pharmacology.

[17]  B. Shenoy,et al.  Stability of crystalline proteins. , 2001, Biotechnology and bioengineering.

[18]  P. Leavis,et al.  The solubility of fibrinogen in dilute salt solutions. , 1974, Archives of biochemistry and biophysics.

[19]  Chung C. Hsu,et al.  Effect of Moisture on the Stability of a Lyophilized Humanized Monoclonal Antibody Formulation , 2001, Pharmaceutical Research.

[20]  A. Minton,et al.  Confinement as a determinant of macromolecular structure and reactivity. , 1992, Biophysical journal.

[21]  D. Kalonia,et al.  Steady-state tryptophan fluorescence spectroscopy study to probe tertiary structure of proteins in solid powders. , 2003, Journal of pharmaceutical sciences.

[22]  Keith Masters,et al.  Spray drying handbook , 1979 .

[23]  T. Arakawa,et al.  Dehydration-induced conformational transitions in proteins and their inhibition by stabilizers. , 1993, Biophysical journal.

[24]  A. Zydney,et al.  Membrane separations in biotechnology. , 2001, Current opinion in biotechnology.

[25]  P. Royall,et al.  Characterisation of the glass transition of HPMC using modulated temperature differential scanning calorimetry. , 1999, International journal of pharmaceutics.

[26]  J. Shiloach,et al.  Tangential flow filtration. , 1988, Advances in biotechnological processes.

[27]  G. Belfort,et al.  Comparison of Ultra‐ and Microfiltration in the Presence and Absence of Secondary Flow with Polysaccharides, Proteins, and Yeast Suspensions , 1998, Biotechnology progress.

[28]  G. Brazeau,et al.  Injectable Drug Development : Techniques to Reduce Pain and Irritation , 1999 .

[29]  W. Jenkins Three solutions of the protein solubility problem. , 1998, Protein science : a publication of the Protein Society.

[30]  M. Manning,et al.  Chemical and physical pathways of protein degradation , 1992 .

[31]  Marc S. Lewis,et al.  Modern analytical ultracentrifugation in protein science: A tutorial review , 2002, Protein science : a publication of the Protein Society.

[32]  Chung C. Hsu,et al.  Fourier‐transform Infrared Spectroscopic Investigation of the Secondary Structure of Aqueous and Dried Recombinant Human Deoxyribonuclease I , 1998 .

[33]  John F. Carpenter,et al.  Physical Stability of Proteins in Aqueous Solution: Mechanism and Driving Forces in Nonnative Protein Aggregation , 2003, Pharmaceutical Research.

[34]  S. Tanabe,et al.  Producing a Low Ovomucoid Egg White Preparation by Precipitation with Aqueous Ethanol , 2000, Bioscience, biotechnology, and biochemistry.

[35]  Arthur J. Rowe,et al.  Analytical ultracentrifugation in biochemistry and polymer science , 1992 .

[36]  P. Schuck Sedimentation analysis of noninteracting and self-associating solutes using numerical solutions to the Lamm equation. , 1998, Biophysical journal.

[37]  J. D. de Pablo,et al.  Stabilization of Lactate Dehydrogenase Following Freeze-Thawing and Vacuum-Drying in the Presence of Trehalose and Borate , 1998, Pharmaceutical Research.

[38]  A. Minton,et al.  Evidence for protein self-association induced by excluded volume. Myoglobin in the presence of globular proteins. , 1981, Biochimica et biophysica acta.

[39]  Peter Schuck,et al.  Size-distribution analysis of proteins by analytical ultracentrifugation: strategies and application to model systems. , 2002, Biophysical journal.

[40]  S. D. Webb,et al.  Freezing bulk-scale biopharmaceuticals using common techniques: and the magnitude of freeze-concentration , 2002 .

[41]  M. Straume,et al.  Comments on the Analysis of Sedimentation Equilibrium Experiments , 1994 .

[42]  P Dunnill,et al.  Action of shear on enzymes: Studies with alcohol dehydrogenase , 1979, Biotechnology and bioengineering.

[43]  R. Pecora Quasi-elastic light scattering from macromolecules. , 1972, Annual review of biophysics and bioengineering.

[44]  T. Arakawa,et al.  Theory of protein solubility. , 1985, Methods in enzymology.

[45]  F. Rothstein Differential precipitation of proteins. Science and technology. , 1994, Bioprocess technology.

[46]  K. Morris,et al.  Accelerated fluid bed drying using NIR monitoring and phenomenological modeling: method assessment and formulation suitability. , 2002, Journal of pharmaceutical sciences.

[47]  A. Saul,et al.  A rapid method of concentrating proteins in small volumes with high recovery using Sephadex G-25. , 1984, Analytical biochemistry.

[48]  S. Shire,et al.  Characterization of complex formation by humanized anti-IgE monoclonal antibody and monoclonal human IgE. , 1995, Biochemistry.

[49]  A. Minton,et al.  Macromolecular crowding: biochemical, biophysical, and physiological consequences. , 1993, Annual review of biophysics and biomolecular structure.

[50]  Theodore W Randolph,et al.  Rational design of stable lyophilized protein formulations: theory and practice. , 2002, Pharmaceutical biotechnology.

[51]  D. Brems,et al.  Inverse Relationship of Protein Concentration and Aggregation , 2002, Pharmaceutical Research.

[52]  T. Laue,et al.  Modern Analytical Ultracentrifugation , 1994, Emerging Biochemical and Biophysical Techniques.

[53]  J L Cleland,et al.  A specific molar ratio of stabilizer to protein is required for storage stability of a lyophilized monoclonal antibody. , 2001, Journal of pharmaceutical sciences.

[54]  P. -. Monte,et al.  Biotechnology-Based Pharmaceuticals , 2002 .

[55]  W. Saenger,et al.  Light Scattering Studies on Supersaturated Protein Solutions , 1999, Science progress.

[56]  J L Cleland,et al.  The development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation. , 1993, Critical reviews in therapeutic drug carrier systems.

[57]  C. Horváth,et al.  Salt effect on hydrophobic interactions in precipitation and chromatography of proteins: an interpretation of the lyotropic series. , 1977, Archives of biochemistry and biophysics.

[58]  Catherine H. Schein,et al.  Solubility as a Function of Protein Structure and Solvent Components , 1990, Bio/Technology.

[59]  P. Waser,et al.  Shear-induced protein-protein interaction at the air-water interface. , 1974, Biochimica et biophysica acta.

[60]  C. Gatlin,et al.  Formulation and Administration Techniques to Minimize Injection Pain and Tissue Damage Associated with Parenteral Products , 1999 .

[61]  S. Shire Analytical Ultracentrifugation and its use in Biotechnology , 1994 .

[62]  T. Arakawa,et al.  Stabilization of protein structure by sugars. , 1982, Biochemistry.

[63]  C. Genovesi Several uses for tangential-flow filtration in the pharmaceutical industry. , 1983, Journal of parenteral science and technology : a publication of the Parenteral Drug Association.

[64]  A. Mire-Sluis,et al.  Immune responses to therapeutic proteins in humans--clinical significance, assessment and prediction. , 2002, Current pharmaceutical biotechnology.

[65]  Jochem Alsenz,et al.  Protein Aggregates Seem to Play a Key Role Among the Parameters Influencing the Antigenicity of Interferon Alpha (IFN-α) in Normal and Transgenic Mice , 1997, Pharmaceutical Research.

[66]  R. Borchardt,et al.  Stability of Protein Pharmaceuticals , 1989, Pharmaceutical Research.